VISEN Pharma Cuts Free-Float Further: Buys Back 5,900 Shares on 12 June, Treasury Stock Rises to 125,800

Bulletin Express06-12

VISEN Pharmaceuticals (Cayman) disclosed a fresh on-market share repurchase on 12 June 2026, trimming its issued share base and lifting treasury stock levels.

Key transaction details • Volume repurchased: 5,900 ordinary shares, equal to 0.005 % of the 113.81 million shares outstanding prior to the trade. • Price range: HKD 19.91–20.06 per share; volume-weighted average price: HKD 19.98. • Total consideration: HKD 0.12 million. • All repurchased shares are being held as treasury stock; no cancellations have been executed to date.

Capital structure impact • Issued shares (excluding treasury) fell to 113.80 million. • Treasury shares increased to 125,800, keeping total issued shares unchanged at 113.93 million.

Repurchase mandate utilisation • The current general mandate, approved on 27 June 2025, allows buybacks of up to 11.39 million shares. • Cumulative repurchases under this mandate now stand at 125,800 shares, representing 0.11 % of the authorised limit.

Regulatory window Under Hong Kong Stock Exchange rules, VISEN Pharma is restricted from issuing new shares or disposing of treasury shares until 12 July 2026—30 days after the latest buyback.

The company affirmed that the transaction complied with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160464990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160464990","market":"hk","top_or_hot":-1,"title":"VISEN Pharma Cuts Free-Float Further: Buys Back 5,900 Shares on 12 June, Treasury Stock Rises to 125,800","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (Cayman) disclosed a fresh on-market share repurchase on 12 June 2026, trimming its issued share base and lifting treasury stock levels.</p>\n<p>Key transaction details  \n• Volume repurchased: 5,900 ordinary shares, equal to 0.005 % of the 113.81 million shares outstanding prior to the trade.  \n• Price range: HKD 19.91–20.06 per share; volume-weighted average price: HKD 19.98.  \n• Total consideration: HKD 0.12 million.  \n• All repurchased shares are being held as treasury stock; no cancellations have been executed to date.</p>\n<p>Capital structure impact  \n• Issued shares (excluding treasury) fell to 113.80 million.  \n• Treasury shares increased to 125,800, keeping total issued shares unchanged at 113.93 million.</p>\n<p>Repurchase mandate utilisation  \n• The current general mandate, approved on 27 June 2025, allows buybacks of up to 11.39 million shares.  \n• Cumulative repurchases under this mandate now stand at 125,800 shares, representing 0.11 % of the authorised limit.</p>\n<p>Regulatory window  \nUnder Hong Kong Stock Exchange rules, VISEN Pharma is restricted from issuing new shares or disposing of treasury shares until 12 July 2026—30 days after the latest buyback.</p>\n<p>The company affirmed that the transaction complied with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Cuts Free-Float Further: Buys Back 5,900 Shares on 12 June, Treasury Stock Rises to 125,800</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Cuts Free-Float Further: Buys Back 5,900 Shares on 12 June, Treasury Stock Rises to 125,800\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-12 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (Cayman) disclosed a fresh on-market share repurchase on 12 June 2026, trimming its issued share base and lifting treasury stock levels.</p>\n<p>Key transaction details  \n• Volume repurchased: 5,900 ordinary shares, equal to 0.005 % of the 113.81 million shares outstanding prior to the trade.  \n• Price range: HKD 19.91–20.06 per share; volume-weighted average price: HKD 19.98.  \n• Total consideration: HKD 0.12 million.  \n• All repurchased shares are being held as treasury stock; no cancellations have been executed to date.</p>\n<p>Capital structure impact  \n• Issued shares (excluding treasury) fell to 113.80 million.  \n• Treasury shares increased to 125,800, keeping total issued shares unchanged at 113.93 million.</p>\n<p>Repurchase mandate utilisation  \n• The current general mandate, approved on 27 June 2025, allows buybacks of up to 11.39 million shares.  \n• Cumulative repurchases under this mandate now stand at 125,800 shares, representing 0.11 % of the authorised limit.</p>\n<p>Regulatory window  \nUnder Hong Kong Stock Exchange rules, VISEN Pharma is restricted from issuing new shares or disposing of treasury shares until 12 July 2026—30 days after the latest buyback.</p>\n<p>The company affirmed that the transaction complied with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1160464990","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160464990","pubTimestamp":1781262041,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (Cayman) disclosed a fresh on-market share repurchase on 12 June 2026, trimming its issued share base and lifting treasury stock levels. Key transaction details   • Volume...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN Pharma进一步削减自由流通量：6月12日回购5,900股，库存股升至125,800股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (Cayman) disclosed a fresh on-market share repurchase on 12 June 2026, trimming its issued share base and lifting treasury stock levels.\nKey transaction details  \n• Volume repurchased: 5,900 ordinary shares, equal to 0.005 % of the 113.81 million shares outstanding prior to the trade.  \n• Price range: HKD 19.91–20.06 per share; volume-weighted average price: HKD 19.98.  \n• Total consideration: HKD 0.12 million.  \n• All repurchased shares are being held as treasury stock; no cancellations have been executed to date.\nCapital structure impact  \n• Issued shares (excluding treasury) fell to 113.80 million.  \n• Treasury shares increased to 125,800, keeping total issued shares unchanged at 113.93 million.\nRepurchase mandate utilisation  \n• The current general mandate, approved on 27 June 2025, allows buybacks of up to 11.39 million shares.  \n• Cumulative repurchases under this mandate now stand at 125,800 shares, representing 0.11 % of the authorised limit.\nRegulatory window  \nUnder Hong Kong Stock Exchange rules, VISEN Pharma is restricted from issuing new shares or disposing of treasury shares until 12 July 2026—30 days after the latest buyback.\nThe company affirmed that the transaction complied with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160464990","isCrawlerRequest":true}